News Focus
News Focus
Followers 60
Posts 11377
Boards Moderated 0
Alias Born 01/31/2008

Re: Investor2014 post# 437544

Monday, 10/30/2023 8:54:20 AM

Monday, October 30, 2023 8:54:20 AM

Post# of 517500
Didi Avatar trial fail?

Slow meltdown of stock price, no data yet despite Rett month.

Is the Evil One correct?

ACAD in first place now going into the home stretch to get approved.

ACAD said tonight that its marketing application for trofinetide in Rhett Syndrome has been submitted to the FDA.

https://acadia.com/media/news-releases/acadia-pharmaceuticals-submits-new-drug-application-to-the-u-s-fda-for-trofinetide-for-the-treatment-of-rett-syndrome/

Which is a good reminder that $AVXL promise to do same has... not happened. Failed studies are tough to submit to the FDA.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News